ACRV
What one share of Acrivon Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing our proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform designed to quantify compound-specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights.
Acrivon Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.88 |
|---|---|
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$1.63 |
| Cash and investments | $0.97 |
| Book value | $2.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$9.32 | $0.14 | −$8.16 | — | −$13.45 |
| 2022 | — | −$7.56 | $0.53 | −$7.83 | — | — |
| 2023 | — | −$2.74 | $0.06 | −$1.99 | — | $5.38 |
| 2024 | — | −$2.38 | $0.08 | −$2.03 | — | $5.66 |
| 2025 | — | −$2.02 | $0.04 | −$1.70 | — | $3.56 |